A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

The study examined about 228,000 people in Sweden who had alcohol use disorder and Type 2 diabetes. The people who were ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

In just one week, nearly 7,000 individuals have used the tracker to report that they cannot access their medications, with brand name products containing semaglutide reported as being the most ...

Researchers at Case Western Reserve school of Medicine looked at nearly one million patients in the U.S. with Type 2 diabetes ...